Can intrabodies serve as neuroprotective therapies for parkinson's disease? beginning thoughts

Journal of Parkinson's Disease

Volumn 3, Issue 4, 2013, Pages 581-591

  Bhatt, Mansi A ^a   Messer, Anne ^c,d   Kordower, Jeffrey H ^b  

^a Department of Pharmacology ^*  (United States)

^b RUSH UNIVERSITY MEDICAL CENTER   (United States)

^c STATE UNIVERSITY OF NEW YORK   (United States)

^d Regenerative Research Foundation   (United States)

Author keywords

Alpha synuclein; Intrabodies; Nanobodies; Parkinson's disease

Indexed keywords

ALPHA SYNUCLEIN; ANTIBODY; ANTIGEN; INTRABODY; NAC32 INTRABODY; NANOBODY; NBSYN2 NANOBODY; NBSYN87 NANOBODY; SCFV 6E INTRABODY; SCFV D10 INTRABODY; SCFV D5 INTRABODY; SCFV SYN 10H; SINGLE CHAIN FRAGMENT VARIABLE ANTIBODY; UNCLASSIFIED DRUG; VH14 INTRABODY;

ARTICLE; AUTOIMMUNE DISEASE; BINDING AFFINITY; CELL ENGINEERING; CELL INCLUSION; CELLULAR DISTRIBUTION; DEGENERATIVE DISEASE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HUNTINGTON CHOREA; LEWY BODY; LEWY NEURITE; NEOPLASM; NEUROPROTECTION; NONHUMAN; PARKINSON DISEASE; PRIORITY JOURNAL; PROTEIN AGGREGATION; PROTEIN BINDING; PROTEIN EXPRESSION; PROTEIN FOLDING;

ALPHA-SYNUCLEIN; INTRABODIES; NANOBODIES; PARKINSON'S DISEASE;

ALPHA-SYNUCLEIN; ANTIBODIES; HUMANS; LEWY BODIES; NEUROPROTECTIVE AGENTS; PARKINSON DISEASE; PROTEIN ENGINEERING; PROTEIN FOLDING;

EID: 84898743262     PISSN: 18777171     EISSN: 1877718X     Source Type: Journal    
DOI: 10.3233/JPD-130252     Document Type: Article

References (98)

1. Hoehn MM, & Yahr MD (2001) Parkinsonism: Onset, progression, and mortality 1967. Neurology, 57, S11-S26.
2. Emadi S, Barkhordarian H,Wang MS, Schulz P,&SierksMR (2007) Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. J Mol Biol, 368, 1132-1144.
3. Fearnley JM, & Lees AJ (1991) Ageing and Parkinson's disease: Substantia nigra regional selectivity. Brain, 114(Pt 5), 2283-2301.
4. Goedert M (2001) Alpha-synuclein and neurodegenerative diseases. Nat Rev Neurosci, 2, 492-501.
5. Iwai A, Masliah E, Yoshimoto M, Ge N, Flanagan L, de Silva HA, Kittel A, & Saitoh T (1995) The precursor protein of non-Abeta component of Alzheimer's disease amyloid is a presynaptic protein of the central nervous system. Neuron, 14, 467-475.
6. Hsu LJ, Mallory M, Xia Y, Veinbergs I, Hashimoto M, Yoshimoto M, Thal LJ, Saitoh T, & Masliah E (1998) Expression pattern of synucleins (non-abeta component of Alzheimer's disease amyloid precursor protein/alpha-synuclein) during murine brain development. J Neurochem, 71, 338-344.
7. Clayton DF, & George JM (1998) The synucleins: A family of proteins involved in synaptic function, plasticity, neurodegeneration and disease. Trends Neurosci, 21, 249-254.
8. Chu Y, Le W, Kompoliti K, Jankovic J, Mufson EJ, & Kordower JH (2006) Nurr1 in Parkinson's disease and related disorders. J Comp Neurol, 494, 495-514.
9. Chu Y, Dodiya H, Aebischer P, Olanow CW, & Kordower JH (2009) Alterations in lysosomal and proteasomal markers in Parkinson's disease: Relationship to alpha-synuclein inclusions. Neurobiol Dis, 35, 385-398.
10. Chu Y, Morfini GA, Langhamer LB, He Y, Brady ST, & Kordower JH (2012) Alterations in axonal transport motor proteins in sporadic and experimental Parkinson's disease. Brain, 135, 2058-2073.
11. Eriksen JL, Dawson TM, Dickson DW, & Petrucelli L (2003) Caught in the act: Alpha-synuclein is the culprit in parkinson's disease. Neuron, 40, 453-456.
12. Polymeropoulos MH, Lavedan C, Leroy E, Ide SE, Dehejia A, Dutra A, Pike B, Root H, Rubenstein J, Boyer R, Stenroos ES, Chandrasekharappa S, Athanassiadou A, Papapetropoulos T, Johnson WG, Lazzarini AM, Duvoisin RC, Di Iorio G, Golbe LI, & Nussbaum RL (1997) Mutation in the alpha-synuclein gene identified in families with Parkinson's disease. Science, 276, 2045-2047.
13. Zarranz JJ, Alegre J, Gomez-Esteban JC, Lezcano E, Ros R, Ampuero I, Vidal L, Hoenicka J, Rodriguez O, Atares B, Llorens V, Gomez Tortosa E, del Ser T, Munoz DG, & de Yebenes JG (2004) The new mutation, E46K, of alphasynuclein causes Parkinson and Lewy body dementia. Ann Neurol, 55, 164-173.
14. Singleton AB, Farrer M, Johnson J, Singleton A, Hague S, Kachergus J, Hulihan M, Peuralinna T, Dutra A, Nussbaum R, Lincoln S, Crawley A, Hanson M, Maraganore D, Adler C, Cookson MR, Muenter M, Baptista M, Miller D, Blancato J, Hardy J, & Gwinn-Hardy K (2003) Alpha-synuclein locus triplication causes Parkinson's disease. Science 302, 841.
15. Kwok JB, Teber ET, Loy C, Hallupp M, Nicholson G, Mellick GD, Buchanan DD, Silburn PA, & Schofield PR (2004) Tau haplotypes regulate transcription and are associated with Parkinson's disease. Ann Neurol, 55, 329-334.
16. Zhou W, Hurlbert MS, Schaack J, Prasad KN, & Freed CR (2000) Overexpression of human alpha-synuclein causes dopamine neuron death in rat primary culture and immortalized mesencephalon-derived cells. Brain Res, 866, 33-43.
17. Feany MB, & Bender WW (2000) A drosophila model of Parkinson's disease. Nature, 404, 394-398.
18. Masliah E, Rockenstein E, Veinbergs I, Mallory M, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, Games D, & Schenk D (2000) Dopaminergic loss and inclusion body formation in alpha-synuclein mice: Implications for neurodegenerative disorders. Science, 287, 1265-1269.
19. Eslamboli A, Romero-Ramos M, Burger C, Bjorklund T, Muzyczka N, Mandel RJ, Baker H, Ridley RM, & Kirik D (2007) Long-term consequences of human alpha-synuclein overexpression in the primate ventral midbrain. Brain, 130, 799-815.
20. Giasson BI, Murray IV, Trojanowski JQ,&LeeVM(2001) A hydrophobic stretch of 12 amino acid residues in the middle of alpha-synuclein is essential for filament assembly. J Biol Chem, 276, 2380-2386.
21. CooksonMR(2009) Alpha-synuclein and neuronal cell death. Mol Neurodegener, 4, 9-1326-4-9.
22. Lynch SM, Zhou C, & Messer A (2008) An scFv intrabody against the nonamyloid component of alpha-synuclein reduces intracellular aggregation and toxicity. J Mol Biol, 377, 136-147.
23. Periquet M, Fulga T, Myllykangas L, Schlossmacher MG, & Feany MB (2007) Aggregated alpha-synuclein mediates dopaminergic neurotoxicity in vivo. J Neurosci, 27, 3338-3346.
24. Conway KA, Harper JD, & Lansbury PT (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med, 4, 1318-1320.
25. Giasson BI, Uryu K, Trojanowski JQ, & Lee VM (1999) Mutant and wild type human alpha-synucleins assemble into elongated filaments with distinct morphologies in vitro. J Biol Chem, 274, 7619-7622.
26. Serpell LC, Berriman J, Jakes R, Goedert M, & Crowther RA (2000) Fiber diffraction of synthetic alpha-synuclein filaments shows amyloid-like cross-beta conformation. Proc Natl Acad Sci U S A, 97, 4897-4902.
27. Uversky VN, Li J, & Fink AL (2001) Metal-triggered structural transformations, aggregation, and fibrillation of human alpha-synuclein. A possible molecular NK between Parkinson's disease and heavy metal exposure. J Biol Chem, 276, 44284-44296.
28. Uversky VN, Li J,&FinkAL(2001) Pesticides directly accelerate the rate of alpha-synuclein fibril formation: A possible factor in Parkinson's disease. FEBS Lett, 500, 105-108.
29. Cohlberg JA, Li J, Uversky VN, & Fink AL (2002) Heparin and other glycosaminoglycans stimulate the formation of amyloid fibrils from alpha-synuclein in vitro. Biochemistry, 41, 1502-1511.
30. Campbell BC, Li QX, Culvenor JG, Jakala P, Cappai R, Beyreuther K, Masters CL, & McLean CA (2000) Accumulation of insoluble alpha-synuclein in dementia with Lewy bodies. Neurobiol Dis, 7, 192-200.
31. Volles MJ, & Lansbury PT Jr (2003) Zeroing in on the pathogenic form of alpha-synuclein and its mechanism of neurotoxicity in Parkinson's disease. Biochemistry, 42, 7871-7878.
32. Lashuel HA, Hartley D, Petre BM, Walz T, & Lansbury PT Jr (2002) Neurodegenerative disease: Amyloid pores from pathogenic mutations. Nature, 418, 291.
33. Emadi S, Barkhordarian H,Wang MS, Schulz P,&SierksMR (2007) Isolation of a human single chain antibody fragment against oligomeric alpha-synuclein that inhibits aggregation and prevents alpha-synuclein-induced toxicity. J Mol Biol, 368, 1132-1144.
34. Huston JS, Margolies MN, & Haber E (1996) Antibody binding sites. Adv Protein Chem, 49, 329-450.
35. Huston JS, Levinson D, Mudgett-Hunter M, TaiMS, Novotny J, Margolies MN, Ridge RJ, Bruccoleri RE, Haber E, & Crea R (1988) Protein engineering of antibody binding sites: Recovery of specific activity in an anti-digoxin single-chain fv analogue produced in escherichia coli. Proc Natl Acad Sci U S A, 85, 5879-5883.
36. Harmsen MM, & De Haard HJ (2007) Properties, production, and applications of camelid single-domain antibody fragments. Appl Microbiol Biotechnol, 77, 13-22.
37. Roovers RC, van Dongen GA, & van Bergen en Henegouwen PM(2007) Nanobodies in therapeutic applications. Curr Opin Mol Ther, 9, 327-335.
38. Habicht G, Haupt C, Friedrich RP, Hortschansky P, Sachse C, Meinhardt J, Wieligmann K, Gellermann GP, Brodhun M, Gotz J, Halbhuber KJ, Rocken C, Horn U, & Fandrich M (2007) Directed selection of a conformational antibody domain that prevents mature amyloid fibril formation by stabilizing abeta protofibrils. Proc Natl Acad Sci U S A, 104, 19232-19237.
39. Chartier A, Raz V, Sterrenburg E, Verrips CT, van der Maarel SM, & Simonelig M (2009) Prevention of oculopharyngeal muscular dystrophy by muscular expression of llama single-chain intrabodies in vivo. Hum Mol Genet, 18, 1849-1859.
40. Lo AS, Zhu Q, & Marasco WA (2008) Intracellular antibodies (intrabodies) and their therapeutic potential. Handb Exp Pharmacol, 181, 343-373.
41. Tanaka T, Williams RL, & Rabbitts TH (2007) Tumour prevention by a single antibody domain targeting the interaction of signal transduction proteins with RAS. EMBO J, 26, 3250-3259.
42. Groot AJ, Gort EH, van derWall E, van Diest PJ, & VooijsM (2008) Conditional inactivation of HIF-1 using intrabodies. Cell Oncol, 30, 397-409.
43. MillerTW,&Messer A (2005) Intrabody applications in neurological disorders: Progress and future prospects. Mol Ther, 12, 394-401.
44. Messer A, Lynch SM, & Butler DC (2009) Developing intrabodies for the therapeutic suppression of neurodegenerative pathology. Expert Opin Biol Ther, 9, 1189-1197.
45. Messer A, & Joshi SN (2013) Intrabodies as neuroprotective therapeutics. Neurotherapeutics, 10, 447-458.
46. Khoshnan A, Ko J, & Patterson PH (2002) Effects of intracellular expression of anti-huntingtin antibodies of various specificities on mutant huntingtin aggregation and toxicity. Proc Natl Acad Sci U S A, 99, 1002-1007.
47. Wang CE, Zhou H, McGuire JR, Cerullo V, Lee B, Li SH, & Li XJ (2008) Suppression of neuropil aggregates and neurological symptoms by an intracellular antibody implicates the cytoplasmic toxicity of mutant huntingtin. J Cell Biol, 181, 803-816.
48. Wolfgang WJ,MillerTW,Webster JM, Huston JS, Thompson LM, Marsh JL, & Messer A (2005) Suppression of huntington's disease pathology in drosophila by human single-chain fv antibodies. Proc Natl Acad Sci U S A, 102, 11563-11568.
49. Snyder-Keller A, McLear JA, Hathorn T, & Messer A (2010) Early or late-stage anti-N-terminal huntingtin intrabody gene therapy reduces pathological features in B6.HDR6/1 mice. J Neuropathol Exp Neurol, 69, 1078-1085.
50. Southwell AL, Ko J, & Patterson PH (2009) Intrabody gene therapy ameliorates motor, cognitive, and neuropathological symptoms in multiple mouse models of Huntington's disease. J Neurosci, 29, 13589-13602.
51. Joshi SN, Butler DC, & Messer A (2012) Fusion to a highly charged proteasomal retargeting sequence increases soluble cytoplasmic expression and efficacy of diverse anti-synuclein intrabodies. MAbs, 4, 686-693.
52. Zhou C, Emadi S, Sierks MR, & Messer A (2004) A human single-chain fv intrabody blocks aberrant cellular effects of overexpressed alpha-synuclein. Mol Ther, 10, 1023-1031.
53. Griffiths AD,Williams SC, Hartley O, Tomlinson IM,Waterhouse P, Crosby WL, Kontermann RE, Jones PT, Low NM, & Allison TJ (1994) Isolation of high affinity human antibodies directly from large synthetic repertoires. EMBO J, 13, 3245-3260.
54. Paxinou E, Chen Q, Weisse M, Giasson BI, Norris EH, Rueter SM, Trojanowski JQ, Lee VM, & Ischiropoulos H (2001) Induction of alpha-synuclein aggregation by intracellular nitrative insult. J Neurosci, 21, 8053-8061.
55. Maries E, Dass B, Collier TJ, Kordower JH, & Steece-Collier K (2003) The role of alpha-synuclein in Parkinson's disease: Insights from animal models. Nat Rev Neurosci, 4, 727-738.
56. El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, Schlossmacher MG, & Allsop D (2006) Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J, 20, 419-425.
57. Masliah E, Rockenstein E, Adame A, Alford M, Crews L, Hashimoto M, Seubert P, Lee M, Goldstein J, Chilcote T, Games D, & Schenk D (2005) Effects of alpha-synuclein immunization in a mouse model of Parkinson's disease. Neuron, 46, 857-868.
58. Emadi S, Kasturirangan S,Wang MS, Schulz P, & Sierks MR (2009) Detecting morphologically distinct oligomeric forms of alpha-synuclein. J Biol Chem, 284, 11048-11058.
59. Kvam E, Nannenga BL, Wang MS, Jia Z, Sierks MR, & Messer A (2009) Conformational targeting of fibrillar polyglutamine proteins in live cells escalates aggregation and cytotoxicity. PLoS One, 4, e5727.
60. Barkhordarian H, Emadi S, Schulz P, & Sierks MR (2006) Isolating recombinant antibodies against specific protein morphologies using atomic force microscopy and phage display technologies. Protein Eng Des Sel, 19, 497-502.
61. Ellisdon AM, Pearce MC, & Bottomley SP (2007) Mechanisms of ataxin-3 misfolding and fibril formation: Kinetic analysis of a disease-associated polyglutamine protein. J Mol Biol, 368, 595-605.
62. Scherzinger E, Lurz R, Turmaine M, Mangiarini L, Hollenbach B, Hasenbank R, Bates GP, Davies SW, Lehrach H, & Wanker EE (1997) Huntingtin-encoded polyglutamine expansions form amyloid-like protein aggregates in vitro and in vivo. Cell, 90, 549-558.
63. De Genst EJ, GuilliamsT,Wellens J, O'Day EM,Waudby CA, Meehan S, Dumoulin M, Hsu ST, Cremades N, Verschueren KH, Pardon E,Wyns L, Steyaert J, Christodoulou J,&Dobson CM (2010) Structure and properties of a complex of alphasynuclein and a single-domain camelid antibody. J Mol Biol, 402, 326-343.
64. GuilliamsT, El-Turk F, Buell AK, O'Day EM, Aprile FA, Esbjorner EK, Vendruscolo M, Cremades N, Pardon E, Wyns L, Welland ME, Steyaert J, Christodoulou J, Dobson CM, & De Genst E (2013) Nanobodies raised against monomeric alphasynuclein distinguish between fibrils at different maturation stages. J Mol Biol, 425, 2397-2411.
65. White DA, Buell AK, Dobson CM,Welland ME, & Knowles TP (2009) Biosensor-based label-free assays of amyloid growth. FEBS Lett, 583, 2587-2592.
66. Buell AK, White DA, Meier C, Welland ME, Knowles TP, & Dobson CM (2010) Surface attachment of protein fibrils via covalent modification strategies. J Phys Chem B, 114, 10925-10938.
67. Knowles TP, Shu W, Devlin GL, Meehan S, Auer S, Dobson CM, & Welland ME (2007) Kinetics and thermodynamics of amyloid formation from direct measurements of fluctuations in fibril mass. Proc Natl Acad Sci U S A, 104, 10016-10021.
68. Kalia LV, Kalia SK, McLean PJ, Lozano AM, & Lang AE (2013) Alpha-synuclein oligomers and clinical implications for Parkinson disease. Ann Neurol, 73, 155-169.
69. Bartels T, Choi JG, & Selkoe DJ (2011) Alpha-synuclein occurs physiologically as a helically folded tetramer that resists aggregation. Nature, 477, 107-110.
70. Wang W, Perovic I, Chittuluru J, Kaganovich A, Nguyen LT, Liao J, Auclair JR, Johnson D, Landeru A, Simorellis AK, Ju S, Cookson MR, Asturias FJ, Agar JN, Webb BN, Kang C, Ringe D, Petsko GA, Pochapsky TC, & Hoang QQ (2011) A soluble alpha-synuclein construct forms a dynamic tetramer. Proc Natl Acad Sci U S A, 108, 17797-17802.
71. Fauvet B, Mbefo MK, Fares MB, Desobry C, Michael S, Ardah MT, Tsika E, Coune P, Prudent M, Lion N, Eliezer D, Moore DJ, Schneider B, Aebischer P, El-Agnaf OM, Masliah E, & Lashuel HA (2012) Alpha-synuclein in central nervous system and from erythrocytes, mammalian cells, and escherichia coli exists predominantly as disordered monomer. J Biol Chem, 287, 15345-15364.
72. Walsh DM, Lomakin A, Benedek GB, Condron MM, & Teplow DB (1997) Amyloid beta-protein fibrillogenesis. Detection of a protofibrillar intermediate. J Biol Chem, 272, 22364-22372.
73. Conway KA, Harper JD, & Lansbury PT (1998) Accelerated in vitro fibril formation by a mutant alpha-synuclein linked to early-onset Parkinson disease. Nat Med, 4, 1318-1320.
74. Lashuel HA, Petre BM, Wall J, Simon M, Nowak RJ, Walz T, & Lansbury PT Jr (2002) Alpha-synuclein, especially the Parkinson's disease-associated mutants, forms pore-like annular and tubular protofibrils. J Mol Biol, 322, 1089-1102.
75. Harper JD, Lieber CM, & Lansbury PT Jr (1997) Atomic force microscopic imaging of seeded fibril formation and fibril branching by the Alzheimer's disease amyloid-beta protein. Chem Biol, 4, 951-959.
76. Wacker JL, ZareieMH,Fong H, Sarikaya M,&Muchowski PJ (2004) Hsp70 and Hsp40 attenuate formation of spherical and annular polyglutamine oligomers by partitioning monomer. Nat Struct Mol Biol, 11, 1215-1222.
77. Outeiro TF, Putcha P, Tetzlaff JE, Spoelgen R, KokerM, Carvalho F, Hyman BT, & McLean PJ (2008) Formation of toxic oligomeric alpha-synuclein species in living cells. PLoS One, 3, e1867.
78. Tetzlaff JE, Putcha P, Outeiro TF, Ivanov A, Berezovska O, Hyman BT, & McLean PJ (2008) CHIP targets toxic alpha-synuclein oligomers for degradation. J Biol Chem, 283, 17962-17968.
79. Putcha P, Danzer KM, Kranich LR, Scott A, Silinski M, Mabbett S, Hicks CD, Veal JM, Steed PM, Hyman BT, & McLean PJ (2010) Brain-permeable small-molecule inhibitors of Hsp90 prevent alpha-synuclein oligomer formation and rescue alpha-synuclein-induced toxicity. J Pharmacol Exp Ther, 332, 849-857.
80. Kalia LV, Kalia SK, Chau H, Lozano AM, Hyman BT, & McLean PJ (2011) Ubiquitinylation of alpha-synuclein by carboxyl terminus Hsp70-interacting protein (CHIP) is regulated by bcl-2-associated athanogene 5 (BAG5). PLoS One, 6, e14695.
81. Danzer KM, RufWP, Putcha P, Joyner D, Hashimoto T, Glabe C, Hyman BT, & McLean PJ (2011) Heat-shock protein 70 modulates toxic extracellular alpha-synuclein oligomers and rescues trans-synaptic toxicity. FASEB J, 25, 326-336.
82. Sharon R, Bar-Joseph I, Frosch MP, Walsh DM, Hamilton JA, & Selkoe DJ (2003) The formation of highly soluble oligomers of alpha-synuclein is regulated by fatty acids and enhanced in Parkinson's disease. Neuron, 37, 583-595.
83. Kruger R,KuhnW, Muller T,Woitalla D, Graeber M,Kosel S, Przuntek H, Epplen JT, Schols L, & Riess O (1998) Ala30Pro mutation in the gene encoding alpha-synuclein in Parkinson's disease. Nat Genet, 18, 106-108.
84. Greenbaum EA, Graves CL, Mishizen-Eberz AJ, Lupoli MA, Lynch DR, Englander SW, Axelsen PH, & Giasson BI (2005) The E46K mutation in alpha-synuclein increases amyloid fibril formation. J Biol Chem, 280, 7800-7807.
85. El-Agnaf OM, Salem SA, Paleologou KE, Curran MD, Gibson MJ, Court JA, Schlossmacher MG, & Allsop D (2006) Detection of oligomeric forms of alpha-synuclein protein in human plasma as a potential biomarker for Parkinson's disease. FASEB J, 20, 419-425.
86. Neumann M, Kahle PJ, Giasson BI, Ozmen L, Borroni E, Spooren W, Muller V, Odoy S, Fujiwara H, Hasegawa M, Iwatsubo T, Trojanowski JQ, Kretzschmar HA, & Haass C (2002) Misfolded proteinase K-resistant hyperphosphorylated alpha-synuclein in aged transgenic mice with locomotor deterioration and in human alpha-synucleinopathies. J Clin Invest, 110, 1429-1439.
87. Fujiwara H, Hasegawa M, Dohmae N, Kawashima A, Masliah E, GoldbergMS,Shen J,Takio K,&IwatsuboT(2002) Alphasynuclein is phosphorylated in synucleinopathy lesions. Nat Cell Biol, 4, 160-164.
88. Hartl FU, Bracher A, & Hayer-Hartl M (2011) Molecular chaperones in protein folding and proteostasis. Nature, 475, 324-332.
89. Tyedmers J, Mogk A, & Bukau B (2010) Cellular strategies for controlling protein aggregation. Nat Rev Mol Cell Biol, 11, 777-788.
90. [Anonymous] (1984) Aetiology of Parkinson's disease. Lancet, 1, 167.
91. Collier TJ, Kanaan NM, & Kordower JH (2011) Ageing as a primary risk factor for Parkinson's disease: Evidence from studies of non-human primates. Nat Rev Neurosci, 12, 359-366.
92. Kourtis N, & Tavernarakis N (2011) Cellular stress response pathways and ageing: Intricate molecular relationships. EMBO J, 30, 2520-2531.
93. Bezard E, & Przedborski S (2011) A tale on animal models of Parkinson's disease. Mov Disord, 26, 993-1002.
94. Dauer W, Kholodilov N, Vila M, Trillat AC, Goodchild R, Larsen KE, Staal R, Tieu K, Schmitz Y, Yuan CA, Rocha M, Jackson-Lewis V, Hersch S, Sulzer D, Przedborski S, Burke R, & Hen R (2002) Resistance of alpha-synuclein null mice to the parkinsonian neurotoxin MPTP. Proc Natl Acad Sci U S A, 99, 14524-14529.
95. Betarbet R, Sherer TB, MacKenzie G, Garcia-Osuna M, Panov AV, & Greenamyre JT (2000) Chronic systemic pesticide exposure reproduces features of Parkinson's disease. Nat Neurosci, 3, 1301-1306.
96. Karpinar DP, Balija MB, Kugler S, Opazo F, Rezaei-Ghaleh N, Wender N, Kim HY, Taschenberger G, Falkenburger BH, Heise H, Kumar A, Riedel D, Fichtner L, Voigt A, Braus GH, Giller K, Becker S, Herzig A, Baldus M, Jackle H, Eimer S, Schulz JB, Griesinger C, & Zweckstetter M (2009) Prefibrillar alpha-synuclein variants with impaired beta-structure increase neurotoxicity in Parkinson's disease models. EMBO J, 28, 3256-3268.
97. Winner B, Jappelli R, Maji SK, Desplats PA, Boyer L, Aigner S, Hetzer C, Loher T,Vilar M, Campioni S, Tzitzilonis C, Soragni A, Jessberger S, Mira H, Consiglio A, Pham E, Masliah E, Gage FH, & Riek R (2011) In vivo demonstration that alpha-synuclein oligomers are toxic. Proc Natl Acad Sci U S A, 108, 4194-4199.
98. Tsika E, Moysidou M, Guo J, Cushman M, Gannon P, Sandaltzopoulos R, Giasson BI, Krainc D, Ischiropoulos H, & Mazzulli JR (2010) Distinct region-specific alpha-synuclein oligomers in A53T transgenic mice: Implications for neurodegeneration. J Neurosci, 30, 3409-3418.